Exact Sciences Corporation

Equities

EXAS

US30063P1057

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-13 pm EDT			5-day change	1st Jan Change
53.52 ^USD	-0.91%		-2.46%	-4.75%

Jun. 04	Exact Sciences Corporation, Q1 2025 Earnings Call, May 01, 2025
Jun. 03	Exact Sciences Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 08:40 AM

Exact Sciences Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10:40 AM

Published on 05/14/2025 at 06:00, updated on 05/14/2025 at 13:40

Presenter Speech
Michael Ryskin (Analysts)

Thanks, everyone, for joining us. My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team.

And

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Exact Sciences Corporation

Exact Sciences Corporation, Q1 2025 Earnings Call, May 01, 2025	Jun. 04
Exact Sciences Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 08:40 AM	Jun. 03
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect? Test and Molecular Residual Disease Innovation Roadmap	May. 28	CI
Exact Sciences Announces Expanded Clinical Validation Of Oncodetect Test And Molecular Residual Disease Innovation Roadmap	May. 28	RE
Exact Sciences Corp. Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025	May. 22	CI
Exact Sciences Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10:40 AM	May. 14
US FDA approves first at-home test for cervical cancer screening	May. 09	RE
RBC Raises Price Target on Exact Sciences to $54 From $52, Keeps Sector Perform Rating	May. 02	MT
Exact Sciences Q1 Adjusted Loss Narrows, Revenue Rises; Shares Up	May. 01	MT
Earnings Flash (EXAS) Exact Sciences Posts Q1 Loss $-0.21 Per Share, vs. FactSet Est of $-0.25	May. 01	MT
Earnings Flash (EXAS) Exact Sciences Posts Q1 Revenue $706.8M, vs. FactSet Est of $688.6M	May. 01	MT
Exact Sciences Corporation Revises Earnings Guidance for the Year 2025	May. 01	CI
Exact Sciences Corporation Reports Unaudited Consolidated Impairment of Long-Lived and Indefinite-Lived Assets for the First Quarter Ended Mar. 31, 2025	May. 01	CI
Exact Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 01	CI
Exact Sciences Corporation Appoints Leslie Trigg as A Class II Member of the Board	Apr. 29	CI
Exact Sciences Launches the Oncodetect Molecular Residual Disease Test	Apr. 22	CI
Exact Sciences Corp. Announces Publication of Comprehensive Review in JAMA Oncology That Strengthens the Evidence Supporting the Oncotype DX Breast Recurrence Score Test	Apr. 14	CI
Mizuho Initiates Exact Sciences at Outperform With $60 Price Target	Apr. 10	MT
Exact Sciences Corp. Launches the Cologuard Plus?? Test, Transforming Colorectal Cancer Screening	Mar. 31	CI
Consumer Spending and the Inflation Fear	Mar. 28
Analyst recommendations: Illumina, Boeing, Next, Walmart, Applovin....	Mar. 28
Sera Prognostics appoints Jeff Elliott to board	Mar. 19	RE
Sera Prognostics Inc. Announces Board Changes	Mar. 19	CI
RBC Initiates Exact Sciences at Sector Perform With $52 Price Target	Mar. 13	MT
Exact Sciences Corporation Announces the Presentation of New Data Further Confirming the Utility of Its Oncotype Dx Breast Recurrence Score®? Test At the 19thst. Gallen International Breast Cancer Conference in Vienna, Austria	Mar. 12	CI